Mystic Ventures, LP - F1 is the latest quarterly vehicle in a rolling venture-fund program whose SEC history stretches back to 2021. The October 6, 2026 Form D reports approximately $74,200 offered, $69,700 already sold to seven investors and a $1,000 minimum investment. That small fund size should not be mistaken for a newly established sponsor: SEC filing history shows at least 19 Mystic vehicles across A-, B-, C-, D-, E- and now F-series partnerships, while Mystic's own website says the rolling fund has operated continuously since 2021 and invests primarily in psychedelic medicines, neuroplastogens, CNS drug development and clinical infrastructure. The more important concern is not whether Mystic exists—it clearly does—but an apparent regulatory-description conflict: F1 is reported under Rule 506(b), while Mystic's current public website says its rolling fund is offered under Rule 506(c), allows general solicitation and uses AngelList to verify accredited-investor status. That mismatch deserves a direct explanation before investors rely on either disclosure.
KEY FINDINGS
Mystic Ventures F1 reported its first sale on October 1, 2026 and filed its initial Form D on October 6. The five-day interval is comfortably inside the SEC's normal 15-day Form D filing period.
The vehicle is classified as a venture capital fund, relies on Section 3(c)(1) and, according to the current Form D data reviewed, claims Rule 506(b).
Seven investors had purchased approximately $69,700 of interests against a total offering of roughly $74,200. That means most of the initial quarterly vehicle was already subscribed when the notice was filed.
The reported minimum investment is $1,000.
That figure is materially lower than historical public descriptions of Mystic's rolling-fund subscription amounts, but Form D asks for the minimum amount accepted from an outside investor and does not necessarily reflect the standard advertised quarterly subscription. A manager can accept a smaller amount from a particular investor without making it the ordinary commercial minimum.
A FIVE-YEAR QUARTERLY FILING TRAIL
The strongest evidence behind Mystic is not F1 itself.
SEC filings show a remarkably consistent quarterly sequence:
A1 through A4; B1 through B4; C1 through C4; D1 through D4; E1 through E4; and F1 beginning in October 2026.
Earlier vehicles appear approximately every three months.
E2 filed in January 2026. E3 followed in April. E4 followed in July. F1 followed in October.
Mystic's current website independently describes exactly this type of structure. It explains that investors subscribe by quarter, capital is called quarterly and each calendar quarter is legally its own fund so investors receive exposure only to investments made during the periods in which they are subscribed.
That alignment between SEC filing cadence and the sponsor's public explanation is a strong structural verification point.
A new CIK every quarter therefore does not mean Mystic launches an unrelated management business every quarter. It reflects the architecture of the rolling fund.
THE CURRENT FUND IS MUCH SMALLER THAN MANY EARLIER QUARTERS
F1's approximately $74,200 offering is notable because many historical Mystic vehicles were materially larger.
Public filing history shows multiple earlier quarterly vehicles reporting several hundred thousand dollars of capital, and some older quarters approached or reached approximately $1 million.
For example, historical records show earlier B-series vehicles around the $1 million level, while several C-, D- and E-series partnerships raised several hundred thousand dollars each.
F1 therefore begins at the smaller end of Mystic's historical quarterly fundraising range.
That should not automatically be called deterioration.
The filing was made only five days after first sale, so additional capital may not be possible once the fixed quarterly offering is filled, and the final size may simply reflect the subscription cohort for that period.
But investors evaluating the health of the rolling fund should compare quarterly commitments over time rather than assuming continuous growth.
A sponsor with five years of rolling-fund history gives investors enough public data to perform that comparison.
THE BIGGEST REGULATORY QUESTION: 506(b) OR 506(c)
The most important negative finding is an apparent inconsistency between Mystic's latest Form D record and its public website.
F1's filing is reported under Rule 506(b).
Mystic's current website, however, states that the rolling fund is open only to accredited investors and is offered under Rule 506(c). The website goes further, explaining that Rule 506(c) permits general solicitation and advertising and that AngelList independently verifies investors' accredited status during subscription.
Those are not minor wording differences.
Rule 506(b) and Rule 506(c) are distinct exemptions.
Rule 506(c) permits general solicitation provided all purchasers are accredited investors and the issuer takes reasonable steps to verify accredited status.
Rule 506(b), by contrast, generally does not permit general solicitation.
Mystic operates a public website containing an "Invest" page, extensive fund information and an AngelList investment link. The current FAQ expressly explains that the fund uses 506(c) because it permits public advertising.
Yet the F1 filing data reviewed identify 506(b).
That apparent inconsistency requires clarification.
It does not prove a securities-law violation.
Possible explanations could include a recently changed exemption, separate or parallel investment structures, an outdated website description, an incorrect Form D selection or another legal distinction not visible publicly.
But an investor should not simply ignore the discrepancy.
A sophisticated diligence process should request written confirmation from fund counsel identifying which exemption applies to F1 specifically and whether public solicitation activity relates to that exact vehicle.
OLDER MYSTIC FILINGS ALSO SHOW 506(b)
The issue is more interesting because F1 does not appear to be an isolated filing choice.
Earlier SEC filings for Mystic E1 and other quarterly partnerships also identify the Rule 506(b) exemption.
This suggests a longer-running Form D pattern rather than a one-time clerical anomaly in F1.
At the same time, the current Mystic website very explicitly describes a 506(c) model.
That makes the timing of any exemption transition important.
If Mystic changed from 506(b) to 506(c), investors should be able to determine when that occurred and which quarterly partnerships were affected.
If the website describes one offering while F1 is a separate 506(b) vehicle, that distinction should also be clearly disclosed.
For FilingDossier, the appropriate conclusion is therefore not "Mystic violated Rule 506(b)." It is: the public regulatory filing and current marketing description appear inconsistent and need reconciliation.
WHO ACTUALLY RUNS MYSTIC
The fund's legal infrastructure and investment team are two different layers.
Historical Mystic Form D filings identify Fund GP, LLC as general partner and Belltower Fund Group, Ltd. as agent of the general partner.
The Lynnwood, Washington address is part of that fund-administration infrastructure and appears across many other rolling funds.
It should not be mistaken for Mystic Ventures' independent investment headquarters.
The actual investment organization is publicly associated with Jeremy Gardner, Mystic's founder and managing partner.
Mystic's current team page also identifies Mack Luby as Associate Partner and describes additional investor-relations personnel.
Gardner's background includes founding Augur, working with Blockchain Capital and later founding Ausum Ventures before focusing on psychedelic and neurotherapeutic investments.
That public operating identity is materially different from the legal Fund GP/Belltower structure visible in Form D.
BELLTOWER IS THE ADMINISTRATIVE LAYER
Historical Mystic filings identify Belltower Fund Group as agent of the general partner.
Belltower is associated with the AngelList fund-administration ecosystem and provides infrastructure for investment vehicles, including fund administration and related operational functions.
This provides a credible explanation for why Mystic's legal address and related-person structure resemble many other rolling funds.
It also means Belltower should not automatically be presented as Mystic's investment manager.
The Mystic team selects the investments.
Belltower and the legal GP infrastructure occupy a different operational layer.
Failing to separate those roles can produce a misleading manager profile.
FORM ADV REVEALS ANOTHER LAYER
Earlier Mystic vehicles appear in official Form ADV disclosures filed by Platform Advisor, LLC.
The ADV identifies Platform Advisor under SEC File No. 802-78135 and specifically lists earlier Mystic partnerships such as Mystic Ventures A2, A3 and A4 as private funds for which information is being reported.
That provides a useful adviser-level regulatory trail beyond Form D.
However, F1 is new, and we did not verify a current detailed ADV private-fund disclosure specifically naming F1.
Therefore, it would be premature to state that Platform Advisor is definitely the current contractual investment adviser to F1.
Form ADV is updated periodically, and a newly created quarterly partnership may not appear immediately.
The historical relationship is real.
The current F1 relationship still needs direct confirmation.
A HIGH-RISK BIOTECH THESIS
The most important investment risk comes from Mystic's strategy itself.
Mystic's current website focuses heavily on early-stage biotechnology involving psychedelic medicines, neuroplastogens and central-nervous-system therapies.
These are not low-risk venture investments.
Drug-development businesses face long clinical timelines, high research costs, trial failures, manufacturing challenges, intellectual-property disputes and regulatory risk.
Mystic itself acknowledges the difficulty of CNS drug development and describes conventional brain-development programs as having very low probabilities of moving successfully from Phase 1 to approval.
The manager argues that psychedelic and neuroplastogen programs may have advantages because many compounds have prior human-use data, potentially large effect sizes and different mechanisms from conventional psychiatric drugs.
That is the bullish thesis.
Investors still bear clinical failure risk.
A compound can demonstrate encouraging early results and still fail in larger trials, encounter safety concerns or receive an unfavorable regulatory decision.
FDA outcomes can radically change private-company valuations in a matter of days.
THE PORTFOLIO CONTAINS REAL COMPANIES — BUT F1'S PORTFOLIO IS NOT YET KNOWN
Mystic publicly lists a substantial sponsor-level portfolio.
Its current website includes companies such as Freedom Biosciences, Stillmind Therapeutics, Spiritus Bioscience, 2A Biosciences, Mindstate Design Labs, Lophora, Journey Clinical, Heading Health, Enthea and others across drug development, clinical infrastructure, neurotechnology and wellness.
That is useful evidence that Mystic has actually deployed capital in its stated field.
But investors should not assume every historical Mystic portfolio company is owned by F1.
The rolling-fund structure means each quarter is legally separate and receives exposure only to investments made during that subscription period.
F1 therefore needs to be evaluated based on the investments allocated to the October 2026 quarter, not the aggregate portfolio accumulated since 2021.
This is an important distinction for marketing.
A sponsor can show an impressive five-year portfolio even though a new investor owns only a small subset of it.
THE ROLLING-FUND MODEL CREATES VINTAGE RISK
Traditional venture funds diversify deployment over several years inside one legal partnership.
Mystic's rolling model splits exposure across quarterly vehicles.
That gives investors flexibility, but it also introduces timing risk.
An investor subscribing during a particularly strong quarter may receive attractive portfolio companies.
Another investor entering a later quarter may receive completely different investments at higher valuations or during a weaker opportunity set.
The manager's long-term sponsor performance therefore does not automatically equal the return of any single quarterly fund.
An F1 investor needs to know which investments F1 actually receives.
This makes quarterly allocation policy an important diligence question.
HOW ARE FOLLOW-ONS ALLOCATED
Mystic's public materials say the rolling structure lets it continue deploying into companies as they develop.
That can be attractive when the manager has winners deserving follow-on capital.
It also raises allocation questions.
If an attractive portfolio company raises another round, which quarterly vehicle gets the allocation
Does a follow-on belong only to the current quarter
Can older quarterly vehicles participate
Are separate SPVs created
Mystic has historically discussed creating SPVs for larger exposure or follow-on investments.
Those choices can materially affect the economics experienced by different LP cohorts.
The operating documents should explain the allocation policy and how conflicts between rolling-fund vehicles and SPVs are managed.
FEE ECONOMICS ALSO NEED TO BE READ AT THE QUARTERLY LEVEL
Mystic's current FAQ states that management fees and carried interest apply at the level of each quarterly vehicle and to capital deployed during that period.
Historical public discussions of the rolling fund described conventional venture-style management-fee and carried-interest economics.
Investors should rely on current offering documents rather than old interviews or promotional posts for the exact percentages.
This matters because a rolling structure can create different fee timing from a traditional ten-year fund.
Investors should understand how fees apply when they subscribe for multiple consecutive quarters, how organizational and administrative costs are allocated and whether SPVs carry additional fees or carry.
The $1,000 Form D minimum does not answer any of those questions.
PSYCHEDELIC INVESTMENT HAS UNIQUE REGULATORY RISK
Some Mystic portfolio companies develop traditional pharmaceutical candidates based on psychedelic or neuroplastogen mechanisms.
Others operate within a broader psychedelic-treatment ecosystem.
That sector faces unusual regulatory and policy uncertainty.
Controlled-substance rules, clinical standards, physician-supervision requirements, FDA approval pathways and state-level reforms can all affect commercialization.
A change in public sentiment or policy can also shift capital availability rapidly.
The industry experienced a major speculative cycle earlier in the decade, followed by a significant downturn across many public psychedelic companies.
Mystic's current website explicitly references investing through the category's "winter."
That history is relevant.
Investors should not assume that renewed scientific interest guarantees attractive venture returns.
WHAT WE THINK
Mystic Ventures F1 has a strong sponsor-verification profile.
The fund is not anonymous.
The website is substantive.
The investment team is public.
The strategy is clearly defined.
The SEC filing history runs continuously across approximately five years of quarterly vehicles.
Earlier Mystic partnerships also appear in Form ADV records, giving the sponsor a deeper regulatory footprint than a one-off Form D issuer.
Those are meaningful positives.
The biggest weakness is the apparent regulatory-description inconsistency between the latest Form D and Mystic's current public website.
A rolling fund publicly advertising itself as a 506(c) offering while the newest quarterly vehicle reports 506(b) deserves a straightforward legal explanation.
The investment strategy itself also remains high risk because seed-stage CNS and psychedelic biotech can experience extreme binary outcomes.
RISK POINTS
The first risk is the apparent Rule 506 mismatch. F1 is reported under 506(b), while Mystic's current website expressly describes its rolling fund as a Rule 506(c) offering using public solicitation and accredited-investor verification.
The second risk is biotech failure. Seed and pre-seed therapeutic companies can lose most or all of their value after unsuccessful trials or regulatory setbacks.
The third risk is psychedelic-specific regulation. Controlled-substance law, FDA decisions and clinical-treatment rules can affect commercialization.
The fourth risk is quarterly vintage concentration. F1 investors receive the investments allocated to F1, not Mystic's entire historical portfolio.
The fifth risk is follow-on allocation. Investors should understand how attractive later rounds are divided among quarterly vehicles and standalone SPVs.
The sixth risk is small F1 scale. Roughly $69,700 had been raised from seven investors, substantially below many historical Mystic quarters.
The seventh risk is service-provider complexity. Fund GP, Belltower, Platform Advisor and the Mystic investment team occupy different layers and should not be described interchangeably.
The eighth risk is fee layering. Quarterly fund fees, administration expenses and separate SPV economics may all influence net returns.
The ninth risk is adviser attribution. Platform Advisor has a verified historical ADV relationship with earlier Mystic funds, but an F1-specific current Schedule D match was not verified.
The tenth risk is performance portability. Strong outcomes in earlier Mystic portfolio companies would not automatically belong to F1 investors.
FINAL ASSESSMENT
Mystic Ventures, LP - F1 has a genuine October 2026 Form D reporting approximately $69,700 sold to seven investors toward an offering of roughly $74,200. The first sale occurred five days before filing, so there is no obvious Form D lateness problem.
The sponsor behind the vehicle is also unusually easy to verify. Mystic has operated publicly since 2021, its website identifies Jeremy Gardner and its investment team, and the SEC record shows a continuous sequence of quarterly partnerships from A1 through F1. Earlier Mystic funds also appear in Platform Advisor's official Form ADV disclosures.
This substantially reduces issuer-identity risk.
The strongest negative finding is instead regulatory consistency. The latest F1 filing is reported under Rule 506(b), while Mystic's current website explicitly says the rolling fund operates under Rule 506(c), permits general solicitation and uses AngelList to verify accredited-investor status. Those two public descriptions should be reconciled in writing before an investor relies on the fund's exemption status.
That discrepancy does not by itself establish misconduct, and there may be a legitimate structural or timing explanation. But it is specific, material and more important than repeating the generic statement that Form D is not SEC approval.
The investment strategy also carries substantial fundamental risk. Mystic concentrates on seed-stage CNS, psychedelic and neuroplastogen companies where clinical trials, intellectual property, financing availability and regulatory decisions can create binary outcomes. The sponsor's five-year portfolio history is useful, but F1 investors receive only the investments allocated to their quarterly vehicle.
We found no public evidence sufficient to characterize Mystic Ventures F1 as a confirmed scam. The more appropriate conclusion is that the sponsor and rolling-fund structure are well documented, while F1 investors should demand clarity on the 506(b)/506(c) discrepancy, current adviser relationship, exact quarterly portfolio, fee structure, follow-on allocation policy and historical net returns by quarterly vintage.
For this fund, the most important question is not whether Mystic Ventures exists. It does. The critical question is whether F1's regulatory structure, portfolio allocation and economics match what the public website tells prospective investors they are buying.